CA2295098A1 - Calcium blockers to treat proliferative vitreoretinopathy - Google Patents

Calcium blockers to treat proliferative vitreoretinopathy Download PDF

Info

Publication number
CA2295098A1
CA2295098A1 CA002295098A CA2295098A CA2295098A1 CA 2295098 A1 CA2295098 A1 CA 2295098A1 CA 002295098 A CA002295098 A CA 002295098A CA 2295098 A CA2295098 A CA 2295098A CA 2295098 A1 CA2295098 A1 CA 2295098A1
Authority
CA
Canada
Prior art keywords
compound
patient
glutamate
retinal
proliferative vitreoretinopathy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002295098A
Other languages
English (en)
French (fr)
Inventor
Evan B. Dreyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2295098A1 publication Critical patent/CA2295098A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002295098A 1997-06-30 1998-06-15 Calcium blockers to treat proliferative vitreoretinopathy Abandoned CA2295098A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5196297P 1997-06-30 1997-06-30
US60/051,962 1997-06-30
PCT/US1998/012414 WO1999000129A1 (en) 1997-06-30 1998-06-15 Calcium blockers to treat proliferative vitreoretinopathy

Publications (1)

Publication Number Publication Date
CA2295098A1 true CA2295098A1 (en) 1999-01-07

Family

ID=21974492

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002295098A Abandoned CA2295098A1 (en) 1997-06-30 1998-06-15 Calcium blockers to treat proliferative vitreoretinopathy

Country Status (6)

Country Link
US (4) US6380261B1 (cg-RX-API-DMAC10.html)
EP (1) EP0994709A4 (cg-RX-API-DMAC10.html)
JP (1) JP2002511868A (cg-RX-API-DMAC10.html)
AU (1) AU727080B2 (cg-RX-API-DMAC10.html)
CA (1) CA2295098A1 (cg-RX-API-DMAC10.html)
WO (1) WO1999000129A1 (cg-RX-API-DMAC10.html)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6380261B1 (en) * 1997-06-30 2002-04-30 Allergan Sales, Inc. Calcium blockers to treat proliferative vitreoretinopathy
US20050009884A1 (en) * 1997-06-30 2005-01-13 Dreyer Evan B. Calcium blockers to treat proliferative retinal diseases
AU5251999A (en) * 1998-08-04 2000-02-28 Wisconsin Alumni Research Foundation Method of reducing retinal ganglion cell degeneration
AU761824B2 (en) * 1998-10-27 2003-06-12 Alcon Laboratories, Inc. Treatment of disorders of the outer retina
US6864232B1 (en) 1998-12-24 2005-03-08 Sucampo Ag Agent for treating visual cell function disorder
WO2000038703A1 (en) * 1998-12-24 2000-07-06 R-Tech Ueno, Ltd. Agent for treating visual cell function disorder
JP2002182418A (ja) * 2000-12-11 2002-06-26 Konica Corp 画像形成方法、画像形成装置
FR2822706A1 (fr) * 2001-03-29 2002-10-04 Univ Pasteur Utilisation de composes organiques antagonistes de recepteurs pour le traitement de la degenerescence retinienne
US8557855B2 (en) * 2002-07-03 2013-10-15 Allergan, Inc. Methods of using ryanodine antagonists in treating neural injury
US20050031652A1 (en) * 2003-02-25 2005-02-10 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers
US20050147584A1 (en) * 2004-01-05 2005-07-07 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20070224278A1 (en) * 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050277698A1 (en) * 2004-01-05 2005-12-15 Hughes Patrick M Memantine delivery to the back of the eye
EP1706095B1 (en) 2004-01-20 2008-12-24 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
WO2005097121A1 (en) * 2004-04-06 2005-10-20 Angiogenetics Sweden Ab Angiogenesis-affecting compounds and methods of use thereof
US20050277139A1 (en) * 2004-04-26 2005-12-15 Itzhak Bentwich Methods and apparatus for the detection and validation of microRNAs
US7122128B2 (en) * 2004-04-29 2006-10-17 General Electric Company Phosphors containing borate of terbium, alkaline-earth, and Group-3 metals, and light sources incorporating the same
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US20050244472A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US20070059336A1 (en) * 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US20050244466A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Photodynamic therapy in conjunction with intraocular implants
US8425929B2 (en) * 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US20050244462A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Devices and methods for treating a mammalian eye
US8455656B2 (en) 2004-04-30 2013-06-04 Allergan, Inc. Kinase inhibitors
US20050244471A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
US20050244458A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US20050244478A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Anti-excititoxic sustained release intraocular implants and related methods
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8591885B2 (en) * 2004-04-30 2013-11-26 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US8673341B2 (en) * 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
BRPI0510485A (pt) 2004-04-30 2007-11-13 Allergan Inc implantes inibidores de tirosina cinase intravìtreos biodegradáveis
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
AU2005271700B2 (en) * 2004-07-12 2010-11-11 Allergan, Inc. Opthalmic compositions and methods for treating ophthalmic conditions
JP2008507588A (ja) * 2004-07-26 2008-03-13 アラーガン、インコーポレイテッド 眼の病態を処置する方法
WO2006043965A1 (en) * 2004-10-14 2006-04-27 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US20070167527A1 (en) * 2006-01-13 2007-07-19 Burke James A Memantine for the normalization of visual acuity deficits
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US7911053B2 (en) * 2007-04-19 2011-03-22 Marvell World Trade Ltd. Semiconductor packaging with internal wiring bus
US8829020B2 (en) 2009-07-16 2014-09-09 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
NZ716349A (en) 2009-11-09 2017-07-28 Allergan Inc Compositions and methods for stimulating hair growth
EP2956096A1 (en) 2013-02-15 2015-12-23 Allergan, Inc. Sustained drug delivery implant
JP2017515800A (ja) 2014-04-08 2017-06-15 ザ・メソジスト・ホスピタル iNOS阻害組成物および乳がん治療薬としてのその使用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2534580A1 (fr) * 1982-10-13 1984-04-20 Synthelabo Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
US4755388A (en) * 1984-11-09 1988-07-05 The Regents Of The University Of California Liposome-encapsulated 5-fluoropyrimidines and methods for their use
AU4807790A (en) * 1988-12-05 1990-06-26 Houston Biotechnology Incorporated Therapeutic use of calcium entry blockers in retinal or optic nerve dysfunction
ZA906583B (en) * 1989-08-21 1991-09-25 Beth Israel Hospital Method and composition for the treatment of cutaneous,ocular,and mucosal hypersensitivity,inflammatory,and hyperproliferative conditions using topical preparations of nifedipine
US5521215A (en) * 1989-11-07 1996-05-28 Ramot University Authority For Applied Research And Industrial Development Ltd. NMDA-blocking pharmaceuticals
US5356902A (en) * 1992-11-06 1994-10-18 Eli Lilly And Company Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists
US5922773A (en) * 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
US5602156A (en) * 1993-09-17 1997-02-11 The United States Of America As Represented By The Department Of Health And Human Services Method for inhibiting metalloproteinase expression
US5424321A (en) * 1993-12-08 1995-06-13 Alcon Laboratories, Inc. Compounds having both potent calcium antagonist and antioxidant activity and use thereof as cytoprotective agents
US6013628A (en) * 1994-02-28 2000-01-11 Regents Of The University Of Minnesota Method for treating conditions of the eye using polypeptides
FR2717080B1 (fr) * 1994-03-09 1996-12-13 Synthelabo Utilisation de l'éliprodil et de ses énantiomères pour la préparation de médicaments utiles dans le traitement des neuropathies périphériques et des maladies neurodégénératives centrales.
US5516522A (en) * 1994-03-14 1996-05-14 Board Of Supervisors Of Louisiana State University Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same
US5597809A (en) * 1994-06-23 1997-01-28 Massachusetts Eye & Ear Infirmary Treatment of optic neuritis
US5710165A (en) * 1994-07-06 1998-01-20 Synthelabo Use of polyamine antagonists for the treatment of glaucoma
US5431907A (en) * 1994-08-03 1995-07-11 Abelson; Mark B. Treatment of vascular disorders of the posterior segment of the eye by topical administration of calcium channel blocking agents
US5623051A (en) * 1994-11-10 1997-04-22 University Of Washington Methods and compositions for screening for presynaptic calcium channel blockers
US5604244A (en) * 1995-06-07 1997-02-18 Alcon Laboratories, Inc. Intraocular irrigating solution containing a polyamine antagonist
FR2738567B1 (fr) 1995-09-08 1997-10-17 Synthelabo Derives de alpha-phenylpiperidine-1-propanol, leur preparation et leur application en therapeutique
TR199800407T1 (xx) 1995-09-08 1998-05-21 Synthelabo 4-(Sikloalkil) piperidin ve t�revleri, haz�rlan��lar�, tedavi ama�l� kullan�mlar�.
FR2738568B1 (fr) 1995-09-08 1997-10-17 Synthelabo Derives de 4-(cycloalkyl)piperidines et 4-(cycloalkylalkyl) piperidines, leur preparation et leur application en therapeutique
US6380261B1 (en) 1997-06-30 2002-04-30 Allergan Sales, Inc. Calcium blockers to treat proliferative vitreoretinopathy
AU761824B2 (en) 1998-10-27 2003-06-12 Alcon Laboratories, Inc. Treatment of disorders of the outer retina
US6482854B1 (en) * 1999-03-25 2002-11-19 Massachusetts Eye And Ear Infirmary Glaucoma treatment

Also Published As

Publication number Publication date
US20050192322A1 (en) 2005-09-01
EP0994709A1 (en) 2000-04-26
EP0994709A4 (en) 2006-02-01
US6380261B1 (en) 2002-04-30
US6573280B2 (en) 2003-06-03
US8101635B2 (en) 2012-01-24
AU727080B2 (en) 2000-11-30
US20030199551A1 (en) 2003-10-23
AU7967298A (en) 1999-01-19
WO1999000129A1 (en) 1999-01-07
US7230032B2 (en) 2007-06-12
US20030060510A1 (en) 2003-03-27
JP2002511868A (ja) 2002-04-16

Similar Documents

Publication Publication Date Title
AU727080B2 (en) Calcium blockers to treat proliferative vitreoretinopathy
CA2150933C (en) Glaucoma treatment
US6482854B1 (en) Glaucoma treatment
US5506231A (en) Treatment of aids dementia, myelopathy and blindness
US4694010A (en) Anticonvulsant compositions and method
DE69332048T2 (de) Verfahren zur senkung des augeninnendrucks im auge von säugern unter anwendung von muskarinantagonisten
WO1998037889A1 (en) Use of descarboethoxyloratadine for the manufacture of a medicament for the treatment of urinary incontinence, motion sickness and vertigo
WO1997038693A1 (en) Calcium channel blockers as human conjunctival mast cell degranulation inhibitors for treating ocular allergic conditions
Siegner et al. Effect of calcium channel blockers alone and in combination with antiglaucoma medications on intraocular pressure in the primate eye
EP0557290A4 (fr) Traitement des demences, des myelopathies, des neuropathies peripheriques et des pertes de vision liees au sida.
US4898860A (en) Anticonvulsant composition and method
US20050009884A1 (en) Calcium blockers to treat proliferative retinal diseases
IE53331B1 (en) Amidinourea compositions for use in a method for relieving the discomfort of a human female attendant to menstruation
WO1994021285A1 (de) Neue verwendung einer kombination aus verapamil und trandolapril
Flach Ophthalmic Clinical Pharmacology Reiview: Epinephrine and the Therapy of the Glaucomas
Turner et al. Antihistamines
EP1117404A1 (en) Composition for treatment of light-injured retinal degeneration disease
WO2002043727A1 (en) Treatment of psychiatric disorders with trimethyl-bicyclo[2.2.1]heptane derivatives
JPS6159289B2 (cg-RX-API-DMAC10.html)
MXPA00009465A (en) Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
MXPA00009464A (en) Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
AU1476802A (en) Use of descarboethoxyloratadine for the manufacture of a medicament for the treatment of vertigo

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued